Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) insider Boxer Capital Management, Llc sold 625,000 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $7.05, for a total value of $4,406,250.00. Following the completion of the transaction, the insider now directly owns 7,573,642 shares in the company, valued at $53,394,176.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Tango Therapeutics Stock Down 5.7 %
NASDAQ TNGX opened at $5.93 on Friday. The firm has a market capitalization of $633.60 million, a P/E ratio of -5.25 and a beta of 0.81. The company has a 50-day moving average price of $8.70 and a 200-day moving average price of $8.46. Tango Therapeutics, Inc. has a 52 week low of $5.83 and a 52 week high of $13.01.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.10. The business had revenue of $19.88 million for the quarter, compared to the consensus estimate of $7.39 million. Tango Therapeutics had a negative net margin of 274.04% and a negative return on equity of 44.73%. As a group, equities research analysts anticipate that Tango Therapeutics, Inc. will post -1.27 EPS for the current year.
Hedge Funds Weigh In On Tango Therapeutics
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on TNGX shares. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Tango Therapeutics in a research report on Tuesday, September 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tango Therapeutics in a report on Tuesday, July 9th. Wedbush boosted their price objective on shares of Tango Therapeutics from $11.00 to $13.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Finally, Jefferies Financial Group began coverage on shares of Tango Therapeutics in a research report on Wednesday, July 17th. They set a “buy” rating and a $19.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $15.14.
View Our Latest Research Report on TNGX
Tango Therapeutics Company Profile
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Further Reading
- Five stocks we like better than Tango Therapeutics
- Why Invest in 5G? How to Invest in 5G Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
- Investing In Automotive Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Dividend Capture Strategy: What You Need to Know
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.